The Story of Lilly Kinsale
The farmhouse situated on the site of Lilly Kinsale in 1978
Lilly Kinsale Campus, with Kinsale Harbour in the background
Making a reliable supply of small molecule products was at the heart of our original manufacturing mission in Kinsale when chemical synthesis technology was used to produce our first batches of active pharmaceutical ingredients in the early 1980’s. Continuously improving our capabilities in small molecule manufacturing technology and ensuring the highest standards of operational excellence is always a top priority for the site. With this continuous improvement mindset, the site has developed and diversified into new areas of technology in each decade of its existence.
Since 2010, Kinsale has become a manufacturing centre of excellence for manufacturing scale-up of small molecule medicines in preparation for market launch. In partnership with our U.S.-based Small Molecule Design and Development colleagues, the Kinsale site is now involved in late-phase product development and process optimisation. These activities include product technology transfers and active ingredient manufacturing in support of clinical trials, as well as implementation of new technologies such as advanced analytics and process analytical technology (PAT).
To support this mission, a significant investment in new biotechnology facilities was made and with the completion of these facilities in a previously greenfield area of the site, Lilly Kinsale entered a new era as a dual manufacturing technology campus. The site also expanded its analytical capabilities, with the development of new bio-analytical facilities to support the expansion into biotechnology manufacturing. Existing employees developed new skillsets in all aspects of biotechnology manufacturing and new employees were hired to bring additional skills that were needed to build our new site.
Biotechnology manufacturing commenced in 2011 when the first batches of biological active ingredients were produced in the newly approved facility. Since 2011, the company added two further biotechnology expansions at Kinsale in 2011 and 2017. The team in Kinsale works close in partnership with Bioprocess Research and Development colleagues in the U.S. to scale-up the manufacturing of newly discovered medicines. This partnership between manufacturing and development colleagues also delivers productivity and process improvement projects.
The team involved in the project delivery was recognised with publication of a scientific paper which documented their work and achievements in the journal “Science”. In 2019, the facility was announced as the “Process Innovation” category winner in the prestigious “Facility of the Year” competition run by the International Society of Pharmaceutical Engineers. The partnership between Lilly colleagues in manufacturing and development delivers world-leading facilities for the production of new medicines.